Acutaas Chemicals Q3 Soars: Revenue Up 43%, Guidance Raised Significantly

CHEMICALS
Whalesbook Logo
AuthorIshaan Verma|Published at:
Acutaas Chemicals Q3 Soars: Revenue Up 43%, Guidance Raised Significantly
Overview

Acutaas Chemicals reported a robust Q3 FY26, with revenue soaring 43% YoY to ₹393.2 crore and margins hitting record highs. EBITDA more than doubled to ₹150.7 crore (38.3% margin), and PAT surged 133.7% to ₹106.2 crore (27% margin). Management has upwardly revised FY26 revenue growth guidance to ~30% and EBITDA margin guidance to 32-35%. Strategic diversification into battery and semiconductor chemicals is progressing well, with commercial operations expected from Q1 FY27 for battery chemicals.

📉 The Financial Deep Dive

The Numbers: Acutaas Chemicals delivered an exceptional Q3 FY26. Revenue from operations jumped 43% year-on-year to ₹393.2 crore. This top-line growth was complemented by significant margin expansion. Gross profit climbed 76.1% YoY to ₹224 crore, expanding gross margins to a robust 57%. EBITDA more than doubled, surging 133.7% YoY to ₹150.7 crore, with EBITDA margins improving to 38.3%. Profit After Tax (PAT) showed remarkable growth, up 133.7% YoY to ₹106.2 crore, translating to a strong PAT margin of 27%.

For the nine months ended December 31, 2025 (9M FY26), revenue grew 29.8% YoY to ₹906.6 crore. Both EBITDA and PAT more than doubled compared to the previous year, underscoring sustained operational efficiency and profitability.

The Quality: The company's ability to achieve record-high margins alongside substantial revenue growth indicates strong pricing power and cost management. The significant increase in PAT relative to revenue growth highlights excellent operating leverage and potential one-off tax benefits, though none were explicitly mentioned as exceptional items. The core profitability has clearly strengthened.

The Grill: Management confidently revised its full-year FY26 revenue growth guidance upwards to approximately 30%, up from the earlier projection of 25%, attributing this to a robust order book. Furthermore, the EBITDA margin guidance for FY26 has been upgraded to the 32-35% range, a notable increase from the previous 28-30% band. This revision signals management's confidence in sustained operational performance and market demand.

🚩 Risks & Outlook

The company is making strategic headway in its diversification initiatives. The battery chemicals business inaugurated a new facility block in Jhagadia, with commercial operations anticipated from Q1 FY27. The semiconductor chemicals segment, supported by its BFC business and a South Korean joint venture (Indichem), is showing encouraging traction. Management aims for these three new verticals to become independent, self-sustaining growth engines by FY28. Total capital expenditure for FY26 is projected at ₹220 crore, with an additional ₹130 crore invested in the Indichem JV. The company is confident in sustaining revenue growth above 25% for the next three years. The primary risks lie in the successful execution and ramp-up of these new business segments and managing potential competitive pressures in emerging chemical markets.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.